Abstract
T he fruits of biotechnological research are having a growing impact on the pharmaceutical market.* However, a recent study found that doctors don’t apply the same decision-making process to biotechnological products as they use for conventional pharmaceuticals. The study suggests that understanding these differences could help purchasers and prescribers work together to optimise outcomes when using biotechnology drugs. For example, formulary management strategies for biotechnological products should place greater emphasis on clinical and humanistic outcomes than cost.
Additional information
* see Healthcare News section, this issue, p12; 800750259
Rights and permissions
About this article
Cite this article
Greener, M. Understanding attitudes about biotechnology drugs. Pharmacoecon. Outcomes News 205, 3–4 (1999). https://doi.org/10.1007/BF03295068
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03295068